Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer

NCT01719380 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01719380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01719380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2012
Completion date
February 12, 2019
Enrollment
156 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer